Bellerophon Therapeutics Inc (NASDAQ:BLPH) saw a significant decrease in short interest in November. As of November 15th, there was short interest totalling 1,075,201 shares, a decrease of 59.3% from the October 31st total of 2,644,739 shares. Based on an average daily volume of 253,263 shares, the days-to-cover ratio is currently 4.2 days. Approximately 2.6% of the shares of the stock are short sold.
In other Bellerophon Therapeutics news, major shareholder Associates Iv L. P. Venrock purchased 210,000 shares of the stock in a transaction on Monday, September 17th. The shares were bought at an average price of $1.20 per share, for a total transaction of $252,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Associates Iv L. P. Venrock purchased 50,000 shares of the stock in a transaction on Wednesday, September 5th. The shares were acquired at an average price of $0.85 per share, for a total transaction of $42,500.00. The disclosure for this purchase can be found here. Insiders have acquired 1,170,000 shares of company stock worth $1,328,850 in the last quarter. 57.80% of the stock is currently owned by company insiders.
An institutional investor recently raised its position in Bellerophon Therapeutics stock. Renaissance Technologies LLC grew its position in Bellerophon Therapeutics Inc (NASDAQ:BLPH) by 4.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,213,276 shares of the biotechnology company’s stock after acquiring an additional 54,076 shares during the quarter. Renaissance Technologies LLC owned about 2.07% of Bellerophon Therapeutics worth $1,310,000 as of its most recent SEC filing. Institutional investors own 59.72% of the company’s stock.
NASDAQ BLPH opened at $0.95 on Monday. The company has a market capitalization of $55.75 million, a PE ratio of -1.06 and a beta of -0.21. Bellerophon Therapeutics has a 1-year low of $0.47 and a 1-year high of $3.30.
Bellerophon Therapeutics (NASDAQ:BLPH) last released its earnings results on Wednesday, November 7th. The biotechnology company reported $0.18 earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.30. As a group, sell-side analysts expect that Bellerophon Therapeutics will post -0.47 EPS for the current year.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis.
Featured Story: What is intrinsic value?
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.